Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

sex

Industry

11 Jul 2023

Intiem: Using AI to Innovate Sexual Wellness

There’s a new generation of companies attempting to integrate AI and wellness....

By Microdose NewsDesk

Don’t Miss

10 Jul 2023

News You Might Have Missed: July 10th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed...

By Microdose NewsDesk

Uncategorized

8 Jul 2023

New Study Shows Psilocybin More Cost-Effective Than Traditional Therapies

A new study finds that psilocybin combined with therapy could be more cost-effective at treating major depression disorders than currently used methods....

By Microdose NewsDesk

Finance

6 Jul 2023

COMPASS Pathways Secures $50 Million in Capital

COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Finance

28 Jun 2023

Cybin Reports 2023 Financial Results and Business Highlights

Cybin has reported audited financial results for fiscal year 2023 and recent business highlights....

By Microdose NewsDesk

Industry

27 Jun 2023

PharmaTher Initiates Filing of Abbreviated New Drug Application to the FDA

PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA...

By Microdose NewsDesk
mushrooms

Don’t Miss

26 Jun 2023

News You Might Have Missed: June 26th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed...

By Microdose NewsDesk
FDA psychedelics

Industry

23 Jun 2023

FDA Issues First Draft Guidance on Psychedelic Clinical Trials

The FDA has published new guidance for researchers investigating the use of psychedelic drugs for the treatment of medical conditions....

By Microdose NewsDesk

Industry

23 Jun 2023

Mindset Pharma Receives Approval for Phase II Depression Trial

Mindset Pharma has been granted approval to start a Phase 2 trial for Major Depressive Disorder, using their lead drug candidate MSP-1014...

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.